Weekly Journal of Sickle Cell Disease Publication Update
Stay current with the latest sickle cell research, regulatory updates, and guidelines.
Non-Genotoxic Conditioning to Improve Donor Chimerism in a Mismatched Murine Transplant Model for Sickle Cell Disease
To evaluate whether non-genotoxic antibody-drug conjugate (ADC) conditioning can support donor hematopoietic engraftment in a murine sickle cell disease (SCD) transplant model.
A Phase 1b, Open-label, Multiple-Dose Study Evaluating Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Pociredir in Patients With Sickle Cell Disease (SCD): Trial Design
To assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and biologic activity of pociredir in patients with SCD, including effects on fetal hemoglobin (HbF) and hemolysis.
Breast cancer screening in women with SCD: a single-center exploratory study
To evaluate breast cancer screening utilization and mammographic characteristics among women living with sickle cell disease (SCD).
Preliminary observations on cerebral blood flow and pain sensitivity in adults with SCD
To explore the relationship between cerebral blood flow (CBF) and pain sensitivity in adults with sickle cell disease (SCD).
An international multicenter cohort shows sickle cell disease is no longer uniformly associated with low body weight, with persistent undernutrition alongside increasing overweight and obesity across age groups, genotypes, and countries.
To characterize body mass index (BMI) distribution and associated clinical factors in individuals with sickle cell disease across diverse global settings.
Elevated ambient nitrogen dioxide (NO₂) levels were associated with greater odds of abnormal pulmonary function tests in children and young adults with sickle cell disease (SCD), highlighting an environmental factor that may influence respiratory health in this population.
To evaluate whether ambient air pollution exposures, particularly criteria pollutants, are associated with abnormal pulmonary function tests (PFTs) among young people living with SCD.
A 5-year-old girl with sickle cell disease (Hb SS) and poor hydroxyurea adherence developed concurrent warm autoimmune hemolytic anemia (wAIHA), splenic sequestration, and hyperhemolysis/delayed hemolytic transfusion reaction after transfusion, illustrating the complexity of immune-mediated hemolysis and the role of multidisciplinary, phenotype-matched intervention.
To present a clinical case illustrating the diagnostic and therapeutic challenges when multiple severe hemolytic complications of SCD converge in a single pediatric patient.
In chronically transfused adults with sickle cell disease (SCD), a retrospective analysis found that a substantial subgroup experienced sleep-associated hemoglobin desaturation (SpO₂ ≤ 88% for ≥5 minutes), which was associated with markers of hemolysis and inflammation, underscoring the need to consider sleep-related hypoxemia in comprehensive SCD care.
To characterize the prevalence and clinical correlates of nocturnal hemoglobin desaturation (NHD) in adults with SCD managed with chronic red blood cell exchange transfusion.
A pooled analysis of Phase 2 and Phase 3 clinical trials provides a detailed safety profile of crizanlizumab 5.0 mg/kg in sickle cell disease (SCD), showing predominantly mild to moderate adverse events alongside infrequent but notable serious infections and bleeding events.
To evaluate the safety of crizanlizumab 5.0 mg/kg by pooling adverse-event data across multiple clinical trials in individuals with SCD.
A retrospective analysis of Medicaid-insured children with sickle cell disease (SCD) found that those with longer continuous coverage had significantly better adherence to oral Hydroxyurea (HU), underscoring the role of stable insurance and continuity in optimizing SCD therapy.
To investigate whether the length of continuous Medicaid enrollment (12- vs. 24-month coverage) affects adherence to hydroxyurea among children with SCD.